Egas Moniz School of Health and Science, 2829-511 Caparica, Almada, Portugal.
Nutrition Lab, Applied Nutrition Research Group, Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511 Caparica, Almada, Portugal.
Nutrients. 2024 Nov 4;16(21):3786. doi: 10.3390/nu16213786.
Sjögren's syndrome is a chronic autoimmune disease that causes dry mouth and eyes and can lead to non-Hodgkin's lymphoma in 5-10% of cases after 10 years. Clinical trials have shown that the oral administration of polyunsaturated fatty acids (PUFAs) seems to have a beneficial effect on Sjögren's syndrome.
This literature review provides an overview of the effects of PUFA supplementation on clinical manifestations and inflammatory parameters in Sjögren's syndrome.
We conducted a literature review using the PubMed, Biomed Central, and Cochrane Library electronic databases and using search terms "Sjögren" AND "omega-3"; and "omega-6" AND "fatty acids" AND "oil". This literature review followed the PRISMA guidelines and included randomized clinical trials in humans with or without a control group using the oral administration of PUFA.
From 26 articles found in the databases, a total of 6 articles were included. Of these six trials, five trials showed an effect on clinical manifestations and three trials on inflammatory parameters. Most of the studies did not show a significant effect on the parameters analyzed. One study showed a significant improvement in dry keratoconjunctivitis compared to the control group. The results suggest that PUFAs may improve inflammatory parameters in patients with Sjögren's syndrome.
This literature review supports the idea that the oral administration of PUFA may possess a potential effect on clinical manifestations. However, due to the limited number of studies and the heterogeneity of clinical trial methodology, further investigations should be employed. Understanding the potential mechanism of action of PUFAs on clinical biomarkers in Sjögren's syndrome may clarify their importance in clinical practice for health professionals.
干燥综合征是一种慢性自身免疫性疾病，可导致口干和眼干，并且在 10 年后 5-10%的病例中可导致非霍奇金淋巴瘤。临床试验表明，多不饱和脂肪酸（PUFA）的口服给药似乎对干燥综合征有有益的效果。
本文综述了 PUFAs 补充对干燥综合征临床表现和炎症参数的影响。
我们使用 PubMed、Biomed Central 和 Cochrane Library 电子数据库进行了文献综述，并使用了“Sjögren”和“omega-3”；以及“omega-6”和“脂肪酸”和“油”等搜索词。本文献综述遵循 PRISMA 指南，包括使用 PUFA 口服给药的有或没有对照组的人类随机临床试验。
从数据库中发现的 26 篇文章中，共纳入了 6 篇文章。在这六项试验中，五项试验显示对临床表现有影响，三项试验对炎症参数有影响。大多数研究对分析的参数没有显示出显著的影响。一项研究显示与对照组相比，干燥性角结膜炎有显著改善。结果表明，PUFAs 可能改善干燥综合征患者的炎症参数。
本文献综述支持口服 PUFAs 可能对临床表现具有潜在影响的观点。然而，由于研究数量有限且临床试验方法学的异质性，应进行进一步的研究。了解 PUFAs 对干燥综合征临床生物标志物的潜在作用机制可能阐明其在卫生专业人员临床实践中的重要性。
